Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIRX |
---|---|---|
09:32 ET | 230 | 0.668 |
09:36 ET | 500 | 0.6251 |
09:39 ET | 650 | 0.6475 |
10:03 ET | 200 | 0.632 |
10:06 ET | 5979 | 0.625 |
10:14 ET | 455 | 0.6484 |
10:30 ET | 547 | 0.652 |
10:35 ET | 2000 | 0.668823 |
10:42 ET | 48761 | 0.7808 |
10:44 ET | 26464 | 0.74 |
10:46 ET | 100 | 0.74 |
10:48 ET | 200 | 0.7178 |
10:50 ET | 1586 | 0.6615 |
10:55 ET | 200 | 0.7031 |
10:57 ET | 1012 | 0.6915 |
11:08 ET | 1100 | 0.69 |
11:22 ET | 500 | 0.69 |
11:26 ET | 100 | 0.7124 |
11:38 ET | 4040 | 0.6908 |
11:51 ET | 1356 | 0.6503 |
12:14 ET | 257 | 0.673 |
12:23 ET | 200 | 0.65 |
12:45 ET | 834 | 0.68 |
12:52 ET | 263 | 0.6551 |
12:54 ET | 1500 | 0.655101 |
01:03 ET | 400 | 0.6551 |
01:08 ET | 821 | 0.655 |
01:30 ET | 3520 | 0.6799 |
01:32 ET | 2000 | 0.6775 |
01:53 ET | 200 | 0.6775 |
02:00 ET | 999 | 0.6601 |
02:04 ET | 2100 | 0.6605 |
02:08 ET | 6600 | 0.6551 |
02:18 ET | 500 | 0.65 |
02:22 ET | 5000 | 0.654 |
02:44 ET | 241 | 0.654 |
02:47 ET | 170 | 0.6541 |
03:21 ET | 200 | 0.6749 |
03:27 ET | 100 | 0.674 |
03:39 ET | 100 | 0.6749 |
03:56 ET | 200 | 0.6749 |
03:57 ET | 882 | 0.675 |
03:59 ET | 298 | 0.6738 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Viracta Therapeutics Inc | 26.5M | -0.5x | --- |
Biora Therapeutics Inc | 26.8M | -0.1x | --- |
Alterola Biotech Inc | 27.3M | -7.5x | --- |
Janone Inc | 27.5M | -0.6x | --- |
BioVie Inc | 28.1M | -0.5x | --- |
RenovoRx Inc | 28.3M | -1.6x | --- |
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-1.24 |
Book Value | $0.47 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.